
Dawn Waterworth, GSK Senior Fellow and Senior Director in Human Genetics

Dawn.M.Waterworth@gsk.com



I am a translational genetics expert with 17 years of experience in large pharma. I have deep knowledge of cardiovascular diseases, diabetes, CKD and NASH as well as the discovery and development process. As a GSK senior fellow, I am recognized to be in the top 5% of scientists in GSK. Utilizing my extensive external network, I have led and helped shape many external collaborations in Europe and the US, including many genetics consortia and I was the EPPIA lead for an Innovative Medicines Initiative Public Private partnership (EMIF). I am a thought leader in Pharmacogenetics and senior author of the seminal review of Efficacy Pharmacogenetics in Nature Reviews Genetics. Author of more than 150 publications.

Diptee Kulkarni, Genetics Therapy Area Head, Oncology

diptee.a.kulkarni@gsk.com



An experienced pharmaceutical R&D professional with expertise in cancer genetics and genomics, cancer molecular biology, pharmacogenetics, and precision medicine. A licensed physician with a PhD in cancer molecular biology and genetics. I have extensive experience in understanding the genetic basis of cancer risk and outcomes as well as drug response genetics. My recent work has focused on the application of human genetics to successful drug discovery and development for which I leverage data from publicly available genetic/genomic databases as well as genetic/healthcare data obtained from the real-world setting.

Johannes Freudenberg, Director, Computational Biology & GSK Fellow
johannes.m.freudenberg@gsk.com



I am a computational biologist specializing in developing, implementing, and applying computational and statistical methods for high-throughput genetics, genomics, proteomics, and metabolomics data analyses in molecular biology research and drug discovery. I have been at GSK for the past eight years working in different therapeutic areas including skin, muscle, metabolic, cancer, and inflammatory diseases. Prior to joining GSK, I received a PhD in Bioinformatics from the University of Cincinnati and I did my postdoctoral training at NIEHS/NIH. Besides work, I enjoy traveling, playing Go, listening to podcasts, gardening, soccer, cooking, and spending time with my family.

Alison Acevedo, Computational Biologist, Human Genetics
alison.x.acevedo@gsk.com



I am a computational biologist in the Human Genetics department of GSK. I began this position in July 2019 after defending my PhD in Biomedical Engineering at Rutgers, within the Ioannis Androulakis lab, in June 2019. Currently, I apply computational and statistical methods to analyse high-throughput genetics data, supporting early-target identification primarily within oncology. Of particular interest to me is my current project analysing cis-regulatory data for targets across therapy areas, which I am happy to discuss more during this panel. My transition to industry has been full of opportunity to engage deeply in projects related to Human Genetics and engage with the greater academic community through conferences and seminars. Curiosity is strongly encouraged at GSK and the breadth of therapy areas that we investigate means your personal scientific interests can and will guide the projects that you become involved in. As Human Genetics and Functional Genomics are both growing departments that are actively recruiting, I hope this message encourages you to also apply.